JP2006502195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502195A5 JP2006502195A5 JP2004538994A JP2004538994A JP2006502195A5 JP 2006502195 A5 JP2006502195 A5 JP 2006502195A5 JP 2004538994 A JP2004538994 A JP 2004538994A JP 2004538994 A JP2004538994 A JP 2004538994A JP 2006502195 A5 JP2006502195 A5 JP 2006502195A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridylmethyl
- vitamin
- formula
- compound
- phthalazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 6
- WHOWNXIYXLWMGJ-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)phthalazine Chemical class N=1N=CC2=CC=CC=C2C=1CC1=CC=NC=C1 WHOWNXIYXLWMGJ-UHFFFAOYSA-N 0.000 claims 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- -1 cyano, carboxy Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 241000534944 Thia Species 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 2
- 229960002594 arsenic trioxide Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 229960003284 iron Drugs 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 2
- 229950000578 vatalanib Drugs 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 235000019158 vitamin B6 Nutrition 0.000 claims 2
- 239000011726 vitamin B6 Substances 0.000 claims 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 2
- 235000005282 vitamin D3 Nutrition 0.000 claims 2
- 239000011647 vitamin D3 Substances 0.000 claims 2
- 229940045997 vitamin a Drugs 0.000 claims 2
- 229940011671 vitamin b6 Drugs 0.000 claims 2
- 229940021056 vitamin d3 Drugs 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000011254 conventional chemotherapy Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41317602P | 2002-09-24 | 2002-09-24 | |
| PCT/EP2003/010578 WO2004028542A1 (en) | 2002-09-24 | 2003-09-23 | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502195A JP2006502195A (ja) | 2006-01-19 |
| JP2006502195A5 true JP2006502195A5 (enExample) | 2006-11-09 |
Family
ID=32043216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004538994A Pending JP2006502195A (ja) | 2002-09-24 | 2003-09-23 | 骨髄異形成症候群の処置用医薬の製造のための４−ピリジルメチル−フタラジン誘導体の使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20060128716A1 (enExample) |
| EP (1) | EP1545534B1 (enExample) |
| JP (1) | JP2006502195A (enExample) |
| KR (1) | KR20050074450A (enExample) |
| CN (1) | CN100372535C (enExample) |
| AT (1) | ATE359789T1 (enExample) |
| AU (1) | AU2003299065B2 (enExample) |
| BR (1) | BR0314647A (enExample) |
| CA (1) | CA2499738A1 (enExample) |
| CR (1) | CR7754A (enExample) |
| DE (1) | DE60313344T2 (enExample) |
| EC (1) | ECSP055700A (enExample) |
| ES (1) | ES2285251T3 (enExample) |
| HR (1) | HRP20050281A2 (enExample) |
| MX (1) | MXPA05003161A (enExample) |
| NO (1) | NO20051936L (enExample) |
| PL (1) | PL374696A1 (enExample) |
| PT (1) | PT1545534E (enExample) |
| RS (1) | RS20050228A (enExample) |
| RU (1) | RU2353364C2 (enExample) |
| WO (1) | WO2004028542A1 (enExample) |
| ZA (1) | ZA200502212B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2313201T3 (es) * | 1997-10-15 | 2009-03-01 | Polarx Biopharmaceuticals, Inc. | Composiciones farmaceuticas que comprenden trioxido de arsenico para el tratamiento de un tumor del sistema nervioso central. |
| WO2007030582A2 (en) | 2005-09-09 | 2007-03-15 | Bristol-Myers Squibb Company | Acyclic ikur inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| RU2136308C1 (ru) * | 1994-11-16 | 1999-09-10 | Жемчугов Владислав Евгеньевич | Стимулятор роста костно-мозговых клеток человека |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| AU766081B2 (en) * | 1999-03-30 | 2003-10-09 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| DE60030770T2 (de) * | 1999-12-06 | 2007-09-06 | Rhode Island Hospital | Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen |
-
2003
- 2003-09-23 MX MXPA05003161A patent/MXPA05003161A/es active IP Right Grant
- 2003-09-23 AU AU2003299065A patent/AU2003299065B2/en not_active Ceased
- 2003-09-23 PL PL03374696A patent/PL374696A1/xx not_active Application Discontinuation
- 2003-09-23 WO PCT/EP2003/010578 patent/WO2004028542A1/en not_active Ceased
- 2003-09-23 RS YUP-2005/0228A patent/RS20050228A/sr unknown
- 2003-09-23 US US10/528,914 patent/US20060128716A1/en not_active Abandoned
- 2003-09-23 JP JP2004538994A patent/JP2006502195A/ja active Pending
- 2003-09-23 DE DE60313344T patent/DE60313344T2/de not_active Expired - Lifetime
- 2003-09-23 PT PT03798175T patent/PT1545534E/pt unknown
- 2003-09-23 ES ES03798175T patent/ES2285251T3/es not_active Expired - Lifetime
- 2003-09-23 HR HR20050281A patent/HRP20050281A2/xx not_active Application Discontinuation
- 2003-09-23 CA CA002499738A patent/CA2499738A1/en not_active Abandoned
- 2003-09-23 KR KR1020057004971A patent/KR20050074450A/ko not_active Ceased
- 2003-09-23 AT AT03798175T patent/ATE359789T1/de not_active IP Right Cessation
- 2003-09-23 BR BR0314647-2A patent/BR0314647A/pt not_active IP Right Cessation
- 2003-09-23 CN CNB038227118A patent/CN100372535C/zh not_active Expired - Fee Related
- 2003-09-23 EP EP03798175A patent/EP1545534B1/en not_active Expired - Lifetime
- 2003-09-23 RU RU2005112711/14A patent/RU2353364C2/ru not_active IP Right Cessation
-
2005
- 2005-03-16 ZA ZA200502212A patent/ZA200502212B/en unknown
- 2005-03-17 CR CR7754A patent/CR7754A/es not_active Application Discontinuation
- 2005-03-23 EC EC2005005700A patent/ECSP055700A/es unknown
- 2005-04-20 NO NO20051936A patent/NO20051936L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533748A5 (enExample) | ||
| EP0622076B1 (en) | Inhibitor for restenosis after percutaneous coronary arterioplasty | |
| JP2001518517A5 (enExample) | ||
| RU2375058C2 (ru) | Комбинации, включающие эпотилоны, и их фармацевтическое применение | |
| JP2005501825A5 (enExample) | ||
| AU2002328921A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| KR100812693B1 (ko) | 항종양 효과 증강제 및 항종양제 | |
| JP2006502195A5 (enExample) | ||
| JP2009292837A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| US6881751B2 (en) | Medicament containing platinum complex compounds and the use thereof | |
| EP1545534B1 (en) | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes | |
| JP2003535874A (ja) | 置換アクリロイルジスタマイシン誘導体、タキサン類及び／又は代謝拮抗剤を含む腫瘍に対する併用療法 | |
| AU2002251763A1 (en) | Method for treating cancer | |
| JP2006503874A5 (enExample) | ||
| JP2002518467A5 (enExample) | ||
| JP2006507319A5 (enExample) | ||
| JP2006503874A (ja) | Ａｍｍの処置 | |
| AU2008203233A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| EP1581228A1 (en) | Treatment of von hippel lindau disease | |
| WO2006105317A2 (en) | Antitumorigemic drug combination comprising a vegf-inhibitor and a thrombospondin-1 peptidomimetic |